Skip to content

MRI-ASL evaluation of Ginkgo biloba dropping pills on cerebral blood flow perfusion in patients with CCCI: a randomized, double-blind, parallel controlled study

MRI-ASL evaluation of Ginkgo biloba dropping pills on cerebral blood flow perfusion in patients with CCCI: a randomized, double-blind, parallel controlled study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000004044
Enrollment
Unknown
Registered
2020-09-02
Start date
2020-09-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CCCI

Interventions

Sponsors

Dongzhimen Hospital of Beijing University of traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) The age is between 50 and 70 years old, regardless of gender (2) The diagnostic criteria of CCCI were met; (3) Cerebral blood flow was 50-70ml / 100g · min, which met the inclusion criteria; (4) Those who can meet the test requirements; (5) Patients with informed consent and signed informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with acute cardiovascular and cerebrovascular diseases; (2) Patients with previous history of intracerebral hemorrhage; (3) Active ulcer and bleeding tendency, long-term use of anticoagulant drugs (such as warfarin) or taking drugs for promoting blood circulation and removing blood stasis; (4) Patients with severe arrhythmia, atrial fibrillation and heart failure; (5) Patients with severe primary diseases of heart, liver, kidney, hematopoietic system, endocrine system, respiratory system, liver function 1.5 times higher than the upper limit of normal value, and serum creatinine (CR) higher than normal value; (6) Pregnant or lactating women, women with short-term pregnancy plan; (7) Allergic constitution; (8) Any other life-threatening or serious disease that cannot be treated for 6 weeks, so as to affect the evaluation results; (9) Other diseases or mental disorders that the researchers believe may limit the efficacy evaluation or follow-up of patients; (10) Patients who have participated in clinical trials of other drugs in the past 4 weeks.

Design outcomes

Primary

MeasureTime frame
CBF;

Secondary

MeasureTime frame
CBF;CBF;CBF;CBF;TCM syndrome;CBF;

Countries

China

Contacts

Public ContactWu Shengxian

Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine

wushx@sina.com+86 13501382919

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026